Together with the Infectious Disease Research Training Office at National Centre for Infectious Diseases (NCID), NHG Group Research helped coordinate multi-agency R&D efforts in the fight against COVID-19. Some of the initiatives included:
The Partnerships for Capability Transformation (PACT Programme) is a pioneering collaboration between NHG and Enterprise Singapore’s (ESG) Clinician-driven Innovation (CDI) initiative. Under PACT, NHG’s Centre for Medical Technologies and Innovations (CMTi) catalyses partnerships between clinicians and Singapore MedTech companies to co-develop and commercialise innovative healthcare products and solutions that are clinically impactful, and which address global health needs. The first of its kind in public healthcare, the success of the PACT programme in NHG has helped proliferate the adoption of the programme in SingHealth and NUHS.
The National Precision Medicine (NPM) strategy was launched in 2017 as a 10-year plan to enhance and accelerate Singapore’s biomedical research, health outcomes, and economic growth. To achieve this, Precision Health Research, Singapore (PRECISE), was set up as the central entity to drive NPM. In NPM Phase II, which started in April 2021, PRECISE collaborates with research and clinical partners from the Singapore ecosystem, including NHG and LKCMedicine, to study the genetic makeup of 100,000 healthy Singaporeans and up to 50,000 people with specific diseases. The genetic data will be integrated with detailed lifestyle, environmental, and clinical data to yield rich insights into factors that contribute to Asian diseases and conditions. PRECISE is supported by the National Research Foundation Singapore and the National Medical Research Council.